Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 10, 2026 · Multiple disclosures including restructuring or layoffs and leadership change
Syndax Pharmaceuticals Inc
14
Restructuring or layoffs
Jun 10, 2026
| ItemItem | Disclosure |
|---|---|
| Item 1.01 | Entered a material definitive agreement |
| Item 1.02 | Terminated a material definitive agreement |
| Item 2.01 | Completed an acquisition or asset sale |
| Item 2.02 | Released results of operations or financial condition |
| Item 2.03 | Created a direct financial obligation |
| Item 2.04 | Triggered acceleration of financial obligations |
| Item 2.05 | Recorded exit or disposal costs (restructuring, layoffs, closures) |
| Item 2.06 | Recorded a material impairment |
| Item 3.02 | Item 3.02 |
| Item 5.02 | Director or executive officer departure or appointment |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Syndax Pharmaceuticals Inc filed this because it recorded material costs from a restructuring, layoff, facility closure, or similar exit activity that investors must be told about promptly.
) 730 Third Avenue , Floor 9 New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 419-1400 Not Applicable (Former name or former address, if changed since last report. ) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.
This filing reports Item 1.01 (entered a material definitive agreement); Item 1.02 (terminated a material definitive agreement); Item 2.01 (completed an acquisition or asset sale); Item 2.05 (recorded exit or disposal costs (restructuring, layoffs, closures)); Item 2.06 (recorded a material impairment); Item 5.02 (director or executive officer departure or appointment); Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Syndax Pharmaceuticals Inc reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
